Pharma BD Deal Intelligence

Vor Biopharma / RemeGen Co., Ltd.

2026 · Licensing/Option · $356M · Complete

Vor Biopharma amended its June 2025 exclusive license agreement with RemeGen Co., Ltd. to add RC298, RemeGen's proprietary dual-target BAFF/APRIL fusion protein, and certain related compounds as additional licensed products alongside telitacicept. Vor holds development and commercialization rights in all territories outside Greater China. Consideration for the expansion comprises $10 million in cash plus a pre-funded warrant for 2.3 million shares exercisable at $0.0001, with up to $330 million in milestones tied to initial products, up to $300 million tied to additional products, and up to $3.775 billion in sales milestones, plus tiered royalties in the high single-digit to mid-teen percentage range.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal.

Key facts

Related deals

See the full interactive analysis, sources & comparables →